Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.77 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29967893 | 1.00 | OPRD1 (0.77) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL4575803 | 0.89 | CYP1A2 (0.75) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL4576333 | 0.89 | CYP1A2 (0.75) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL251703 | 0.89 | CYP1A2 (0.75) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL4575415 | 0.89 | CYP1A2 (0.75) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL6369045 | 0.89 | CYP1A2 (0.75) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL6934910 | 0.89 | CYP1A2 (0.75) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL4576116 | 0.89 | CYP1A2 (0.75) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL6557493 | 0.89 | CYP1A2 (0.75) | OPRD1OPRM1CYP3A4CYP1A2OPRK1 | |
| SCHEMBL4576182 | 0.89 | CYP3A4 (0.76) | OPRD1OPRM1MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005079767-A2 | MEANS FOR MODULATION OF THE EFFECTS OF OPIOID-LIKE SUBSTANCES | Universitätsklinikum Münster (DE) | 2005-09-01 | — | — | WO | claimed |
| EP-3513792-B9 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASES | NIPPON CHEMIPHAR CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| EP-3513792-B1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASES | NIPPON CHEMIPHAR CO (JP) | 2024-03-27 | — | — | EP | disclosed |
| EP-4299074-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF STRESS-RELATED DISORDERS | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2024-01-03 | — | — | EP | disclosed |
| US-20230141198-A1 | PYRAZOLOMORPHINAN DERIVATIVE | THE KITASATO INSTITUTE (JP) | 2023-05-11 | — | — | US | disclosed |
| US-11643411-B2 | Morphinan derivative | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-20230132191-A1 | USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230054895-A1 | METHODS FOR INDUCING BIOSTASIS IN A CELL, TISSUE OR ORGAN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-23 | — | — | US | disclosed |
| US-20210371422-A1 | MORPHINAN DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| EP-3272750-B1 | MORPHINAN DERIVATIVE | NIPPON CHEMIPHAR CO (JP) | 2021-11-03 | — | — | EP | disclosed |
| US-6444679-B1 | NEUROLOGICAL AND GASTROINTESTINAL DISORDERS; DELTA OPIOID LIGANDS OR OPIOID RECEPTORS | PFIZER INC | 2002-09-03 | — | — | US | disclosed |
| US-20020045755-A1 | Novel methods of O-demethylation and N-deprotection | COOP ANDREW (US) | 2002-04-18 | — | — | US | disclosed |
| US-20020013321-A1 | 4,4-Biarylpiperidine derivatives | PFIZER INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1140835-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6291675-B1 | MIXING OPIOID COMPOUND AND HYDRIDE REAGENT SELECTED FROM THE GROUP CONSISTING OF LITHIUM TRI-SEC-BUTYLBOROHYDRIDE, LITHIUM TRISIAMYLBOROHYDRIDE AND LITHIUM TRIETHYLBOROHYDRIDE TO PRODUCE AN O-DEMETHYLATED OPIOID COMPOUND | THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-09-18 | — | — | US | disclosed |
| EP-1112255-A1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | Pfizer Products Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| EP-1038872-A1 | 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands | Pfizer Products Inc. (US) | 2000-09-27 | — | — | EP | disclosed |
| US-6103722-A | CARDIOPROTECTIVE EFFECT; STIMULATION OF DELTA OPIOID RECEPTOR AGONISTS; ANTIISCHEMIC AGENTS; REDUCING MYOCARDIAL INFARCTION DAMAGE; 4A-(3-HYDROXYPHENYL)-1,2,3,4, 4A,5,12,12A-NAPHTHO(OR QUINOXALINO)(2,3-G)ISOQUINOLINES | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION INC. (US) | 2000-08-15 | — | — | US | disclosed |
| WO-2000039091-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000014066-A1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | PFIZER PRODUCTS INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045755-A1 | Novel methods of O-demethylation and N-deprotection | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885MEN1 4835/4885 |
| US-11643411-B2 | Morphinan derivative | OPRM1, OPRD1, HTR2B | OPRD1 2/4885OPRM1 1/4885MEN1 2049/4885 |
| US-20230141198-A1 | PYRAZOLOMORPHINAN DERIVATIVE | OPRD1, OPRK1, OPRL1 | OPRD1 1/4885OPRM1 4/4885MEN1 4871/4885 |
| US-20210371422-A1 | MORPHINAN DERIVATIVE | OPRM1, HTR2B, HTR3D | OPRD1 4/4885OPRM1 1/4885MEN1 1738/4885 |
| US-20230132191-A1 | USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885MEN1 3444/4885 |
| US-20230054895-A1 | METHODS FOR INDUCING BIOSTASIS IN A CELL, TISSUE OR ORGAN | OPRL1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 6/4885MEN1 4386/4885 |
| US-20020013321-A1 | 4,4-Biarylpiperidine derivatives | CYP4B1, CYP3A5, CYP3A4 | OPRD1 50/4885OPRM1 166/4885MEN1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.